Patents by Inventor John M. McCall

John M. McCall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-hormonal steroid modulators of NF-kB for treatment of disease
    Patent number: 11833159
    Abstract: The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-?B for the treatment or prevention of muscular wasting disease, including muscular dystrophy.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: December 5, 2023
    Assignee: ReveraGen BioPharma, Inc.
    Inventors: John M. McCall, Eric Hoffman, Kanneboyina Nagaraju
  • KDM1A inhibitors for the treatment of disease
    Patent number: 11773068
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Grant
    Filed: September 22, 2021
    Date of Patent: October 3, 2023
    Assignee: Imago Biosciences, Inc.
    Inventors: Hugh Y. Rienhoff, Jr., John M. McCall, Michael Clare, Cassandra Celatka, Amy E. Tapper
  • Inhibitors of dihydroceramide desaturase for treating disease
    Patent number: 11771684
    Abstract: Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic, cardiovascular, fibrotic, autoimmune/chronic inflammatory diseases, cystic fibrosis, various cancers, neurodegenerative diseases, lipid storage disorders, and ischemia/reperfusion injury, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: October 3, 2023
    Assignee: Centaurus Therapeutics
    Inventors: Donna L. Romero, John M. McCall, Jeremy Blitzer
  • Non-hormonal steroid modulators of NF-?? for treatment of disease
    Patent number: 11690853
    Abstract: The present invention relates to compounds and methods which may be useful as treatments of diseases.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: July 4, 2023
    Assignee: ReveraGen BioPharma, Inc.
    Inventors: John M. McCall, Eric Hoffman, Kanneboyina Nagaraju, Jesse Damsker
  • Acid addition salts, compositions, and methods of treating
    Patent number: 11661409
    Abstract: Provided is a tartrate salt of 3-(1H-indol-5-yl)-5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-b]pyridine and crystalline forms thereof. Also provided are pharmaceutical compositions comprising a tartrate salt disclosed herein and crystalline forms thereof and a pharmaceutically acceptable excipient, and a method of treating a disease or disorder, such as disease or disorder associated with neuroinflammation, comprising administering to a subject in need thereof, a therapeutically effective amount of an acid addition salt disclosed herein or the pharmaceutical composition of the acid addition salt.
    Type: Grant
    Filed: September 13, 2022
    Date of Patent: May 30, 2023
    Assignee: Pioneura Corporation
    Inventors: Harris A. Gelbard, John M. McCall, Jesse Damsker, Arthur Romero
  • KDM1A inhibitors for the treatment of disease
    Patent number: 11655226
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: May 23, 2023
    Assignee: Imago Biosciences, Inc.
    Inventors: John M. McCall, Hugh Y. Rienhoff, Jr., Michael Clare
  • METHODS AND PROCESSES FOR THE PREPARATION OF KDM1A INHIBITORS
    Publication number: 20230104647
    Abstract: Provided in this disclosure are methods for the synthesis of substituted 2-arylcyclopropylamines and 2-heteroarylcyclopropylamines and related compounds. Also provided are methods for reduction of thioesters to aldehydes, and methods for reductive amination of cyclopropylamines.
    Type: Application
    Filed: June 15, 2022
    Publication date: April 6, 2023
    Inventors: Amy E. TAPPER, Cassandra CELATKA, Arthur Glenn ROMERO, John M. MCCALL, Toni CHANCELLOR, Jian-Xie CHEN, Xuemei CHEN, He ZHAO, Betina BIOLATTO, Elisabeth C.A. BROT, Zhihua LI, Xiaoming LIAO
  • Acid addition salts, compositions, and methods of treating thereof
    Patent number: 11479541
    Abstract: Provided is an acid addition salt of 3-(1H-indol-5-yl)-5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-b]pyridine selected from a tartrate salt, a phosphate salt, and a fumarate salt. Also provided are pharmaceutical compositions comprising an acid addition salt disclosed herein and a pharmaceutically acceptable excipient, and a method of treating a disease or disorder, such as disease or disorder associated with neuroinflammation, comprising administering to a subject in need thereof, a therapeutically effective amount of an acid addition salt disclosed herein or the pharmaceutical composition of the acid addition salt.
    Type: Grant
    Filed: January 31, 2022
    Date of Patent: October 25, 2022
    Assignee: Pioneura Corporation
    Inventors: Harris A. Gelbard, John M. McCall, Jesse Damsker, Arthur Romero
  • NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE
    Publication number: 20220324902
    Abstract: The present invention relates to compounds and methods which may be useful as treatments of diseases.
    Type: Application
    Filed: December 10, 2021
    Publication date: October 13, 2022
    Inventors: John M. MCCALL, Eric HOFFMAN, Kanneboyina NAGARAJU, Jesse DAMSKER
  • Heterocyclic compounds for the inhibition of PASK
    Patent number: 11459307
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: October 4, 2022
    Assignee: BioEnergenix LLC
    Inventors: John M. McCall, Donna L. Romero, John McKearn, Michael Clare
  • Methods and processes for the preparation of KDM1A inhibitors
    Patent number: 11390590
    Abstract: Provided in this disclosure are methods for the synthesis of substituted 2-arylcyclopropylamines and 2-heteroarylcyclopropylamines and related compounds. Also provided are methods for reduction of thioesters to aldehydes, and methods for reductive animation of cyclopropylamines.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: July 19, 2022
    Assignee: Imago Biosciences, Inc.
    Inventors: Amy E. Tapper, Cassandra Celatka, Arthur Glenn Romero, John M. McCall, Toni Chancellor, Jian-Xie Chen, Xuemei Chen, He Zhao, Betina Biolatto, Elisabeth C. A. Brot, Zhihua Li, Xiaoming Liao
  • INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE
    Publication number: 20220079926
    Abstract: Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic, cardiovascular, fibrotic, autoimmune/chronic inflammatory diseases, cystic fibrosis, various cancers, neurodegenerative diseases, lipid storage disorders, and ischemia/reperfusion injury, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 17, 2022
    Inventors: Donna L. Romero, John M. McCall, Jeremy Blitzer
  • KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20220073477
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Application
    Filed: September 22, 2021
    Publication date: March 10, 2022
    Inventors: Hugh Y. RIENHOFF, JR., John M. MCCALL, Michael CLARE, Cassandra CELATKA, Amy E. TAPPER
  • COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE AMINOCYCLOPROPANES
    Publication number: 20220025424
    Abstract: The present disclosure relates to compositions and methods for producing stereoisomerically pure aminocyclopropanes.
    Type: Application
    Filed: August 16, 2017
    Publication date: January 27, 2022
    Inventors: Amy E. TAPPER, Cassandra CELATKA, Arthur Glenn ROMERO, John M. MCCALL, Toni CHANCELLOR, He ZHAO, Betina BIOLATTO, Jian-Xie CHEN, Elisabeth C.A. BROT, Peter C. MICHELS, Venkat K. CHARI, Ian C. COTTERILL
  • KDM1A inhibitors for the treatment of disease
    Patent number: 11230534
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: January 25, 2022
    Assignee: Imago Biosciences, Inc.
    Inventors: Hugh Y. Rienhoff, Jr., John M. McCall, Michael Clare, Cassandra Celatka, Amy E. Tapper
  • Inhibitors of dihydroceramide desaturase for treating disease
    Patent number: 11135207
    Abstract: Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic, cardiovascular, fibrotic, autoimmune/chronic inflammatory diseases, cystic fibrosis, various cancers, neurodegenerative diseases, lipid storage disorders, and ischemia/reperfusion injury, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: October 5, 2021
    Assignee: Centaurus Therapeutics
    Inventors: Donna L. Romero, John M. McCall, Jeremy Blitzer
  • HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
    Publication number: 20210198216
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Application
    Filed: August 12, 2020
    Publication date: July 1, 2021
    Inventors: John M. MCCALL, Donna L. ROMERO, John MCKEARN, Michael CLARE
  • KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20210147373
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Application
    Filed: December 1, 2020
    Publication date: May 20, 2021
    Inventors: John M. MCCALL, Hugh Y. RIENHOFF, JR., Michael CLARE
  • METHODS AND PROCESSES FOR THE PREPARATION OF KDM1A INHIBITORS
    Publication number: 20210139437
    Abstract: Provided in this disclosure are methods for the synthesis of substituted 2-arylcyclopropylamines and 2-heteroarylcyclopropylamines and related compounds. Also provided are methods for reduction of thioesters to aldehydes, and methods for reductive animation of cyclopropylamines.
    Type: Application
    Filed: August 16, 2017
    Publication date: May 13, 2021
    Inventors: Amy E. TAPPER, Cassandra CELATKA, Arthur Glenn ROMERO, John M. MCCALL, Toni CHANCELLOR, Jian-Xie CHEN, Xuemei CHEN, He ZHAO, Betina BIOLATTO, Elisabeth C.A. BROT, Zhihua LI, Xiaoming LIAO
  • Heterocyclic compounds for the inhibition of pask
    Patent number: 10953012
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: March 23, 2021
    Assignee: BioEnergenix LLC
    Inventors: John M. McCall, Robert C. Kelly, Donna L. Romero